title: Small Fiber Neuropathy in Children: Two Case Reports Illustrating the Importance of Recognition.
abstract: Small fiber neuropathy (SFN) is a debilitating condition that often leads to pain and autonomic dysfunction. In the last few decades, SFN has been gaining more attention, particularly in adults. However, literature about SFN in children remains limited. The present article reports the cases of 2 adolescent girls diagnosed with SFN. The first patient (14 years of age) complained about painful itch and tingling in her legs, as well as dysautonomia symptoms for years. She also reported a red/purple-type discoloration of her legs aggravated by warmth and standing, compatible with erythromelalgia. The diagnosis of SFN was confirmed by a reduced intraepidermal nerve fiber density (IENFD) in skin biopsy sample. No underlying conditions were found. Symptomatic neuropathic pain treatment was started with moderate effect. The second patient (16 years of age) developed painful sensations in both feet and hands 6 weeks after an ICU admission for diabetic ketoacidosis, which included dysautonomia symptoms. She also exhibited some signs of erythromelalgia. The patient was diagnosed with predominant SFN (abnormal IENFD and quantitative sensory testing) as well as minor large nerve fiber involvement. Treatment with duloxetine, combined with a rehabilitation program, resulted in a marked improvement in her daily functioning. Although the SFN diagnosis in these 2 cases could be established according to the definition of SFN used in adults, additional diagnostic tools are needed that may be more appropriate for children. Additional information about the course of SFN in children may result in better treatment options.
authors.affiliation: Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands; j.hoeijmakers@mumc.nl.
authors.forename: Janneke G J
authors.initials: JG
authors.lastname: Hoeijmakers
authors.affiliation: Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands.
authors.forename: Catharina G
authors.initials: CG
authors.lastname: Faber
authors.affiliation: Departments of Pediatrics, and.
authors.forename: Carien J
authors.initials: CJ
authors.lastname: Miedema
authors.affiliation: Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands.|Department of Neurology, St. Elisabeth Hospital, Willemstad, Curaçao.
authors.forename: Ingemar S J
authors.initials: IS
authors.lastname: Merkies
authors.affiliation: Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands.|Neurology, Catharina Hospital, Eindhoven, Netherlands; and.
authors.forename: Johan S H
authors.initials: JS
authors.lastname: Vles
mesh_terms: D000293:Adolescent; D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D001706:Biopsy; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000068736:Duloxetine Hydrochloride / Q000627:therapeutic use; D004916:Erythromelalgia / Q000209:etiology; D005260:Female; D000077206:Gabapentin; D006801:Humans; D010292:Paresthesia / Q000209:etiology; D011537:Pruritus / Q000209:etiology; D012867:Skin / Q000473:pathology; D000071075:Small Fiber Neuropathy / Q000175:diagnosis* / Q000628:therapy; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000068736:Duloxetine Hydrochloride